 |
|
 Home |
 |
| Overview |
|
| Videos |
|
| Background |
|
| The Science |
|
| Contact Us |
|
| Replikins Press |
|
 |
|
|
The Science Fixed scaffold Replikin peptide sequence in H5N1 "Bird Flu" virus conserved since 1959: Proposed origin from the 1917 Goose Replikin peptide; Design of synthetic Bird Flu vaccine from conserved replikins The current outbreak of high mortality H5N1 "bird flu" in several countries is the cause of some concern because it might represent the first phase of an overdue influenza pandemic. The ability to prepare a vaccine in a timely manner is in doubt because of the egg-based culture methods; and the constant random substitution of amino acids in H5N1 proteins (antigenic drift) is thought not to permit carry-over of an effective vaccine to the next year. The companies scientists have examined the sequences of the common influenza strain proteins published in PubMed by the U.S. National Library of Medicine. Rather than the expected universal random substitutions, we identified an unsubstituted fixed scaffold in the hemagglutinin protein. In H5N1, an orderly internal substitution in the scaffold was conserved from 1959 to the present (Figure). In addition, the company found structural homology with peptides in other influenza strains, H1N1, H1N2, H2N2, H3N2, H5N2, and H7N7, also shown in the Figure. This provides a first glimpse of a memory process which has conserved parts of this peptide sequence scaffold for 86 years, through different strain-dominant epidemics and three influenza pandemics of 1918, 1957, and 1968. The company has synthesized target peptides, found them to be highly immunogenic, and are now entering the target peptides in multi-strain efficacy vaccine trials.  Identical goose peptide amino acid scaffold in blue; amino acid substitutions in yellow and red. 1 2 3 4 5 |
| Recent Press | |
Boston, November 27, 2009 - Biotech firm Replikins Ltd., which has analyzed the H1N1 virus' genomic data from the 1918 pandemic through the prediction, outbreak, and progress of the current H1N1 pandemic, today issued its latest biochemical analysis of the virus... |
|
| New Non-Biological Synthetic Replikins™ Vaccines Shown to Be Effective and Fast; WorldVaccines™, Ltd. Formed for Testing and Distribution Old Biological Vaccines for Emergent Diseases - Too Little, Too Late
Boston, October 19, 2009 - There is increasing evidence that, with best intent, current biological technology cannot supply the world's six billion humans, and animal populations, with vaccines against emerging diseases at a rate that can contend with a disease's rapid appearance and change... |
|
Copyright © 2010 Replikins Ltd. All rights reserved.